Semmelweis University

At Semmelweis University, a major share of the clinical research focuses on cardiovascular disease and related metabolic risk factors. Studies are looking at conditions such as atherosclerotic cardiovascular disease, acute myocardial infarction, atrial fibrillation, heart failure, and elevated lipoprotein(a), with the goal of improving prevention and reducing serious heart-related events.

• Testing new options to lower the risk of major adverse cardiovascular events
• Evaluating treatments for heart failure and hypertrophic cardiomyopathy
• Studying therapies for high cholesterol, hypertriglyceridemia, and other lipid problems

These trials reflect a strong interest in better long-term protection for people at high cardiovascular risk, from early prevention to treatment after a heart event.

The site also supports research in nervous system diseases, especially acute ischemic stroke and prevention of recurrent stroke after a transient ischemic attack. The studies are designed to find safer and more effective ways to lower clot-related complications and improve recovery after a cerebrovascular event.

• Assessing medicines aimed at preventing repeat ischemic stroke
• Comparing treatments used after high-risk transient ischemic attack
• Exploring new approaches for acute stroke care

These investigations address an important need for better secondary prevention in patients who remain vulnerable after a first stroke or warning event.

Research in neoplasms is another key area at the Varosmajori Sziv- es Ergyogyaszati Klinika, with trials spanning non-small cell lung cancer, renal cell carcinoma, bladder cancer, and cutaneous squamous cell carcinoma. The main aim is to evaluate new cancer treatments and combinations that may improve disease control and survival.

• Testing novel immunotherapy strategies in advanced cancers
• Studying treatment options for metastatic lung cancer and renal cancer
• Evaluating therapies for high-risk bladder cancer and skin cancer

These studies show a broad oncology portfolio with a strong focus on improving outcomes for patients with difficult-to-treat or advanced malignancies.

Clinical trials at this site also cover immune-related and organ-specific conditions, including Crohn's disease, chronic rhinosinusitis, and chronic lung allograft dysfunction after transplantation. The research is aimed at easing inflammation, improving symptoms, and supporting better function in affected organs.

• Evaluating treatments for inflammatory bowel disease
• Improving care for persistent sinus disease
• Testing therapies to preserve lung transplant function

This mix of studies highlights a practical focus on chronic inflammatory conditions and the long-term needs of patients living with complex immune and respiratory disorders.

Smaller but important parts of the portfolio address nutritional and metabolic diseases as well as bacterial infections and mycoses. The trials in this group are centered on improving treatment for abnormal blood fats and related risk states, while also supporting broader efforts in infection-related and systemic disease research.

• Studying therapies for severe hypertriglyceridemia
• Investigating treatment approaches for lipoprotein disorders
• Supporting research across metabolic and infection-related disease areas

Overall, the site’s clinical trial activity combines prevention-focused cardiometabolic research with targeted studies in cancer, stroke, inflammation, and chronic organ disease.